T1	Participants 182 385	patients randomised in a previously reported multicentre phase III study of topotecan versus paclitaxel in patients with advanced epithelial ovarian cancer who had failed one prior platinum-based regimen
T2	Participants 408 456	Patients with bidimensionally measurable disease
T3	Participants 957 969	226 patients
